SEATTLE, Aug. 08, 2017 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today reported financial results for the second quarter of 2017.
Second Quarter Financial Highlights
- Total revenue of $34.6 million, 53% year-over-year growth
- Total product and service revenue of $18.3 million, 5% year-over-year growth
- Consumables revenue of $11.0 million, including $1.8 million of Prosigna® IVD kits, 7% year-over-year growth
- Instrument revenue of $6.0 million, 6% year-over-year decline
- Collaboration revenue of $16.3 million, including $11.3 million related to the terminated Medivation and Astellas collaboration agreement
“Overall, we’re pleased with the progress we are making toward our strategic objectives, and we expect the build out of our commercial organization, together with new product introductions, to begin showing positive impact in the second half of the year,” commented Brad Gray, president and chief executive officer of NanoString. “Our pipeline of new instruments, including Digital Spatial Profiling and Hyb & SeqTM, is advancing according to plan and with the funding provided through the collaboration with Lam Research announced today, the future looks even more exciting.”
Recent Business Highlights
- Entered into $50 million development collaboration with Lam Research to advance development of the Hyb & Seq next generation sequencing platform
- Strengthened the balance sheet by raising $56.5 million of net proceeds in a common stock offering
- Grew installed base to approximately 540 nCounter® Analysis Systems at June 30, 2017
- Added 20 new sales positions year to date, expanding the life science sales force by more than 25%
- Hired J. Chad Brown as Senior Vice President, Sales & Marketing to lead commercial operations
- Appointed Elisha W. Finney, former CFO of Varian Medical Systems, to the board of directors
- Record number of abstracts presented by the company, its customers and its collaborators at the annual meeting of the American Society of Clinical Oncology (ASCO)
Second Quarter Financial Results
Revenue for the three months ended June 30, 2017 increased by 53% to $34.6 million, as compared to $22.6 million for the second quarter of 2016. Instrument revenue was $6.0 million, 6% lower than the prior year period, with nCounter® SPRINTTM systems representing approximately 40% of systems sold. Consumables revenue, excluding Prosigna, was $9.2 million for the second quarter of 2017, 1% higher than in the comparable 2016 quarter. Prosigna® IVD kit revenue was $1.8 million for the quarter, an increase of 48% over the second quarter of 2016. Collaboration revenue totaled $16.3 million, which included $11.3 million related to the terminated Medivation and Astellas collaboration agreement, compared to $5.1 million for the second quarter of 2016. Gross margin on product and service revenue was 55% for the second quarter of 2017, comparable with the prior year period.
Research and development expense increased by 25% to $11.0 million for the second quarter of 2017 versus $8.8 million for the second quarter of 2016, reflecting increased costs associated with biopharma collaborations announced in 2016 and investments in new products and technologies under development for the life science research market, including 3D Biology™, Digital Spatial Profiling, and Hyb & Seq technologies. Selling, general and administrative expense increased by 20% to $18.6 million for the second quarter of 2017 compared to $15.5 million for the prior year period, reflecting added staffing, including the expanded sales channel, and other costs supporting the company’s growth.
Net loss for the three months ended June 30, 2017 was $4.6 million, or a loss of $0.20 per share, compared with $10.8 million, or $0.55 per share, for the second quarter of 2016.
Outlook for 2017
On May 18, 2017, when the company reported the termination of the Medivation/Astellas collaboration, total revenue guidance was updated to $106 million to $111 million, but no other aspects of 2017 financial guidance were formally updated. Today, the company has fully updated its guidance for 2017 relative to its original outlook as follows:
- Total revenue in the range of $114 million to $118 million, which was originally $100 million to $105 million
- Product and service revenue in the range of $81 million to $85 million, unchanged
- Gross margin on product and service revenue in the range of 57% to 58%, unchanged
- Operating expenses in the range of $123 million to $126 million, which was previously $117 million to $120 million
- Operating loss in the range of $42 million to $46 million, which was previously $49 million to $53 million
- Net loss per share in the range of $2.03 to $2.20, which was previously $2.51 to $2.69
Management will host a conference call today beginning at 1:30 pm PT / 4:30 pm ET to discuss these results and answer questions. Individuals interested in listening to the conference call may do so by dialing (888) 793-9492 for domestic callers, or (734) 385-2643 for international callers. Please reference Conference ID 50352884. To listen to a live webcast, please visit the investor relations section of the company’s website at: www.nanostring.com. A replay of the call will be available beginning August 8, 2017 at 7:30pm ET through 7:30pm ET on August 15, 2017. To access the replay, dial (855) 859-2056 or (404) 537-3406 and reference Conference ID: 50352884. The webcast will also be available on the company’s website for one year following the completion of the call.
About NanoString Technologies, Inc.
NanoString Technologies provides life science tools for translational research and molecular diagnostic products. The company's nCounter Analysis System has been employed in life sciences research since it was first introduced in 2008 and has been cited in more than 1,600 peer-reviewed publications. The nCounter Analysis System offers a cost-effective way to easily profile the expression of hundreds of genes, proteins, miRNAs, or copy number variations, simultaneously with high sensitivity and precision, facilitating a wide variety of basic research and translational medicine applications, including biomarker discovery and validation. The company's technology is also being used in diagnostics. The Prosigna Breast Cancer Prognostic Gene Signature Assay together with the nCounter Dx Analysis System is FDA 510(k) cleared for use as a prognostic indicator for distant recurrence of breast cancer. In addition, the company is collaborating with multiple biopharmaceutical companies in the development of companion diagnostic tests for various cancer therapies, helping to realize the promise of precision oncology.
For more information, please visit www.nanostring.com.
This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements regarding the impact of changes in the company's commercial organization, the capabilities of the company’s new products and future products under development, development funding and its estimated 2017 operating results. Such statements are based on current assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties, many of which are beyond our control, include market acceptance of our products; delays or denials of regulatory approvals or clearances for products or applications; delays or denials of reimbursement for diagnostic products; the impact of competition; the impact of expanded sales, marketing, product development and clinical activities on operating expenses; delays or other unforeseen problems with respect to manufacturing, product development or clinical studies; adverse conditions in the general domestic and global economic markets; as well as the other risks set forth in the company's filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. NanoString Technologies disclaims any obligation to update these forward-looking statements.
The NanoString Technologies logo, NanoString, NanoString Technologies, Hyb & Seq, nCounter, nCounter SPRINT, and Prosigna are registered trademarks or trademarks of NanoString Technologies, Inc. in various jurisdictions.
|NANOSTRING TECHNOLOGIES, INC.|
|CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS|
|(In thousands, except per share amounts)|
|Three Months Ended|
|Six Months Ended |
|In vitro diagnostic kits||1,835||1,241||3,274||1,995|
|Total product and service revenue||18,310||17,488||34,075||29,624|
|Costs and expenses:|
|Cost of product and service revenue||8,224||7,871||15,387||13,741|
|Research and development||11,038||8,799||21,839||16,007|
|Selling, general and administrative||18,644||15,507||36,210||30,411|
|Total costs and expenses (a) (b)||37,906||32,177||73,436||60,159|
|Loss from operations||(3,314||)||(9,550||)||(20,780||)||(22,835||)|
|Other income (expense):|
|Other income (expense)||184||12||197||(59||)|
|Total other income (expense), net||(1,194||)||(1,220||)||(2,535||)||(2,538||)|
|Net loss before provision for income taxes||(4,508||)||(10,770||)||(23,315||)||(25,373||)|
|Provision for income taxes||(47||)||(35||)||(92||)||(35||)|
|Net loss per share, basic and diluted||$||(0.20||)||$||(0.55||)||$||(1.06||)||$||(1.29||)|
|Shares used in calculating basic and diluted net loss per share||22,672||19,803||22,121||19,736|
|(a) Includes $2.8 million and $2.4 million of stock-based compensation expense for the three months ended June 30, 2017 and |
2016, respectively, and $5.1 million and $4.3 million for the six months ended June 30, 2017 and 2016, respectively.
|(b) Includes $0.9 million and $0.8 million of depreciation and amortization expense for the three months ended June 30, 2017 |
and 2016, respectively, and $1.7 million and $1.5 million for the six months ended June 30, 2017 and 2016, respectively.
|NANOSTRING TECHNOLOGIES, INC.|
|CONDENSED CONSOLIDATED BALANCE SHEETS|
|June 30,||December 31,|
|Cash and cash equivalents||$||40,647||$||20,583|
|Accounts receivable, net||18,482||22,193|
|Prepaid expenses and other||5,305||3,744|
|Total current assets||138,883||113,785|
|Property and equipment, net||13,644||12,158|
|Liabilities and Stockholders’ Equity|
|Deferred revenue, current portion||17,067||19,033|
|Deferred rent, current portion||444||13|
|Lease financing obligations, current portion||—||58|
|Total current liabilities||32,890||36,383|
|Deferred revenue, net of current portion||11,322||22,664|
|Deferred rent and other liabilities, net of current portion||8,669||7,655|
|Long-term debt and lease financing obligations, net of current portion and debt issuance costs||48,137||47,366|
|Total stockholders’ equity||52,024||12,305|
|Total liabilities and stockholders’ equity||$||153,042||$||126,373|
Contact Douglas Farrell Vice President, Investor Relations & Corporate Communications email@example.com Phone: 206-602-1768